FTC Sues Prescription Drug Middlemen for Artificially Inflating …
WEB1 day ago · Today, the Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs, impaired patients’ access to lower ...
FTC Releases Interim Staff Report on Prescription Drug Middlemen
WEBThe Federal Trade Commission today published an interim report on the prescription drug middleman industry that underscores the impact pharmacy benefit managers (PBMs) have on the accessibility and affordability of prescription drugs.
F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices
WEB1 day ago · Rahul Rao, an F.T.C. official, said in a news release on Friday that the largest P.B.M.s “have extracted millions of dollars off the backs of patients who need lifesaving medications.”
FTC sues pharmacy benefit managers for inflating price of insulin …
WEB18 hours ago · The three PBMs named in the FTC lawsuit make up about 80% of the market. According to the suit, the PBMs collected billions of dollars in rebates and fees while insulin became increasingly ...
FTC sues insulin middlemen, saying they pocket ... - Health News …
WEB18 hours ago · In 2019, one 1 of 4 insulin patients was unable to afford their medication, according to the FTC. Some people have died. The Pharmaceutical Care Management Association, which represents PBMs, denied many of the allegations in FTC’s suit, including that PBM rebates correlate with higher list prices.
FTC sues drug middlemen for allegedly inflating insulin prices
WEB1 day ago · The FTC suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts.
FTC Deepens Inquiry into Prescription Drug Middlemen
WEBMay 17, 2023 · As part of its ongoing inquiry into pharmacy benefit managers (PBMs) and their impact on the accessibility and affordability of prescription drugs, the Federal Trade Commission has issu.
F.T.C. Slams Middlemen for High Drug Prices - The New York Times
WEBJul 9, 2024 · The Federal Trade Commission on Tuesday sharply criticized pharmacy benefit managers, saying in a scathing 71-page report that “these powerful middlemen may be profiting by inflating drug costs...
FTC sues CVS, Cigna, UnitedHealth PBMs over insulin prices - STAT
WEB1 day ago · The FTC said CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx profit at the expense of patients forced to pay more for insulin.
Drug middlemen illegally drive up the cost of insulin, FTC says
WEB1 day ago · September 20, 2024 / 3:09 PM EDT / CBS News. Federal regulators are accusing the country's three largest pharmacy benefit managers of illegally driving up the cost of insulin in the U.S., while ...
Skip to content